Blood clot case under investigation following Pfizer vaccine The news comes as Australia moves to establish local mRNA manufacturing capacity and experts call for current Pfizer supplies to be redirected to younger cohorts.
Major reset to vaccination program: What will it mean for GPs? GPs have welcomed the National Cabinet’s proposal to revise the vaccine roadmap but say supply issues must be addressed before any major changes are made.
Blood clots up to 10 times more common with COVID than vaccines: Study Research has identified the various risks of people experiencing cerebral venous thrombosis, which has been linked to the AstraZeneca vaccine.
What would it take for Australia to manufacture mRNA vaccines? Experts say investing in RNA technology now will help to protect Australia, and its neighbours, beyond the current pandemic.
Blood-clot death ‘likely’ linked to AstraZeneca COVID vaccine The TGA has confirmed the recent death of a 48-year-old NSW woman was likely linked to the vaccine: ‘A causative link to vaccination should be assumed at this time’.
‘Seeds of fear and mayhem’: Concerns media hindering vaccine rollout Journalists have a responsibility to not undermine the science and contribute to issues of vaccine hesitancy, according to the RACGP President.
Department of Health eyes vaccine MBS ‘recalibration’ Medicare rebates were one of several issues raised by GPs at a recent primary care webinar on the rollout of the AstraZeneca COVID vaccine.
Blood clots, supply issues, new technologies: Does Australia need another COVID vaccine option? After delays with Novavax, advising against AstraZeneca for under-50s, and ruling out Johnson & Johnson, what are the Government’s remaining options?
‘No change’ in risk profile with second blood clot case linked to AstraZeneca Two cases of clotting in 700,000 administered doses does not indicate an increased level of risk, experts have said.
No legal risk for GPs administering AstraZeneca vaccine: Health Minister Greg Hunt has moved to reassure practitioners amid reports GPs stopped offering AstraZeneca to under-50s following recent ATAGI recommendations.